Along with self-discipline, David Kazan Jr. attributes 20 successful years in pharmaceutical sales to a lasting commitment to his customers.
Along with self-discipline, David Kazan Jr. attributes 20 successful years in pharmaceutical sales to a lasting commitment to his customers. "That's why I've been successful - just letting them know I'm here for the long term," he said. "I let the doctors know what I can do to support them in their practice."
Selling Immunex's oncology products for the past eight years has been rewarding but challenging. Some of Kazan's doctors won't see him more than once every three to four months. This drives Kazan to be even more prepared and knowledgeable when he does see them. From preceptorships to cancer board meetings, he takes every opportunity to learn more about oncology and the needs of his customers and their patients.
Understanding his customers is Kazan's way of doing business: "I always try to look at it from his or her standpoint. If I were the doctor, what type of information would I want from a pharmaceutical representative?"
Kazan tries to keep his own needs in mind, too, and with a five-year-old son and a two-and-a-half-year-old daughter, he has a lot of balancing to do. "It's tough," he said. "Sometimes it's not that easy, but you just have to spend quality time with them and it works out."
Kazan loves what he does and it is evident. "It has to come from within," he stressed. "The person has to really love the profession because a lot of times salespeople are degraded. You have to let your customer know that you're there for the long term and not just for the one-time sale. I think that's really the key."
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.